BCL2 and pancreatic neoplasm: We initially compared the in vitro antitumor effect of two orally bioavailable Bcl-2 inhibitors, ABT-263 and ABT-199, and found that ABT-263 was able to sensitize human pancreatic cancer cells to TRAIL.